Zoetis Inc. (NYSE:ZTS) Shares Purchased by Vinva Investment Management Ltd

Vinva Investment Management Ltd raised its holdings in shares of Zoetis Inc. (NYSE:ZTSFree Report) by 14.7% during the fourth quarter, HoldingsChannel reports. The institutional investor owned 15,331 shares of the company’s stock after acquiring an additional 1,966 shares during the quarter. Vinva Investment Management Ltd’s holdings in Zoetis were worth $3,023,000 at the end of the most recent quarter.

Other institutional investors also recently bought and sold shares of the company. Blue Bell Private Wealth Management LLC boosted its position in shares of Zoetis by 222.5% in the fourth quarter. Blue Bell Private Wealth Management LLC now owns 129 shares of the company’s stock worth $25,000 after buying an additional 89 shares during the period. Independence Bank of Kentucky raised its stake in shares of Zoetis by 371.4% during the fourth quarter. Independence Bank of Kentucky now owns 165 shares of the company’s stock valued at $33,000 after purchasing an additional 130 shares during the period. Private Wealth Management Group LLC purchased a new stake in shares of Zoetis during the fourth quarter valued at approximately $33,000. Ramirez Asset Management Inc. acquired a new position in shares of Zoetis during the third quarter worth $35,000. Finally, Gladius Capital Management LP purchased a new position in shares of Zoetis in the fourth quarter valued at $40,000. 92.80% of the stock is currently owned by hedge funds and other institutional investors.

Zoetis Stock Performance

Shares of NYSE:ZTS traded up $0.11 on Friday, hitting $176.89. The company’s stock had a trading volume of 1,819,439 shares, compared to its average volume of 2,107,329. The company has a market capitalization of $80.71 billion, a price-to-earnings ratio of 34.08, a price-to-earnings-growth ratio of 2.75 and a beta of 0.88. The company has a debt-to-equity ratio of 1.30, a quick ratio of 1.94 and a current ratio of 3.33. Zoetis Inc. has a 12 month low of $144.80 and a 12 month high of $201.92. The stock’s 50-day moving average is $164.77 and its two-hundred day moving average is $179.64.

Zoetis (NYSE:ZTSGet Free Report) last posted its quarterly earnings data on Thursday, May 2nd. The company reported $1.38 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.34 by $0.04. The business had revenue of $2.19 billion during the quarter, compared to analysts’ expectations of $2.14 billion. Zoetis had a net margin of 27.38% and a return on equity of 50.34%. The business’s revenue was up 9.5% on a year-over-year basis. During the same period last year, the firm posted $1.31 earnings per share. On average, equities research analysts forecast that Zoetis Inc. will post 5.76 EPS for the current year.

Zoetis Dividend Announcement

The company also recently announced a quarterly dividend, which will be paid on Wednesday, September 4th. Investors of record on Thursday, July 18th will be paid a dividend of $0.432 per share. The ex-dividend date is Thursday, July 18th. This represents a $1.73 annualized dividend and a yield of 0.98%. Zoetis’s dividend payout ratio is currently 33.14%.

Analyst Upgrades and Downgrades

A number of equities analysts have weighed in on ZTS shares. HSBC decreased their price objective on shares of Zoetis from $230.00 to $225.00 and set a “buy” rating for the company in a research report on Wednesday, May 8th. Piper Sandler reaffirmed an “overweight” rating and issued a $195.00 target price (down from $220.00) on shares of Zoetis in a research report on Tuesday, April 16th. Stifel Nicolaus decreased their price target on shares of Zoetis from $195.00 to $180.00 and set a “buy” rating for the company in a research report on Tuesday, April 30th. Barclays dropped their price target on shares of Zoetis from $260.00 to $230.00 and set an “overweight” rating for the company in a research note on Tuesday, April 23rd. Finally, StockNews.com cut Zoetis from a “strong-buy” rating to a “buy” rating in a research note on Tuesday, February 20th. Eight equities research analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, the company currently has a consensus rating of “Buy” and an average target price of $211.75.

Get Our Latest Stock Report on Zoetis

Insiders Place Their Bets

In other news, EVP Roxanne Lagano sold 923 shares of Zoetis stock in a transaction that occurred on Thursday, April 18th. The shares were sold at an average price of $151.17, for a total value of $139,529.91. Following the transaction, the executive vice president now owns 14,800 shares of the company’s stock, valued at approximately $2,237,316. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. 0.16% of the stock is owned by company insiders.

About Zoetis

(Free Report)

Zoetis Inc engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses.

Recommended Stories

Want to see what other hedge funds are holding ZTS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Zoetis Inc. (NYSE:ZTSFree Report).

Institutional Ownership by Quarter for Zoetis (NYSE:ZTS)

Receive News & Ratings for Zoetis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zoetis and related companies with MarketBeat.com's FREE daily email newsletter.